# Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer

> **NCT00690872** · PHASE2 · UNKNOWN · sponsor: **National Cancer Centre, Singapore** · enrollment: 35 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** autologous Epstein-Barr virus-specific cytotoxic T lymphocytes
- **DRUG:** carboplatin
- **DRUG:** gemcitabine hydrochloride
- **GENETIC:** polymerase chain reaction
- **OTHER:** fluorescence activated cell sorting
- **OTHER:** immunoenzyme technique

## Key facts

- **NCT ID:** NCT00690872
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-07
- **Primary completion:** 2014-12
- **Final completion:** —
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2009-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00690872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00690872, "Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00690872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*